Skip to main content
SpringerLink
Log in

Cutaneous Malignant Melanoma

  • Chapter
Managing Skin Cancer

  • 1044 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Bray F, Pisani P, Parkin DM; GLOBOCAN (2000) Cancer incidence. Mortality and prevalence worldwide, version 1.0. IARC cancer base No.5. IARCPress, Lyon

    Google Scholar 

  2. de Vries E, Bray F, Coebergh JWW et al (2003) Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality, but recent stabilisations in Western Europe and decreases in Scandinavia. Int J Cancer 107:119–126

    Article  PubMed  CAS  Google Scholar 

  3. Karlsson PM, Fredrikson M (2007) Cutaneous malignant melanoma in children and adolescents in Sweden, 1993–2002: the increasing trend is broken. Int J Cancer 121:323–328

    Article  PubMed  CAS  Google Scholar 

  4. Karim-Kos HE, de Vries E, Soerjomataram I et al (2008) Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer Jul;44(10):1345–89. Epub 2008 Feb 14

    Article  Google Scholar 

  5. de Vries E, Houterman S, Janssen-Heijnen M et al (2007) Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands. Ann Oncol 18:1110–1116

    Article  PubMed  Google Scholar 

  6. Verdecchia A, Francisci S, Brenner H et al Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007 8:784–796

    Article  PubMed  Google Scholar 

  7. Lee JA, Carter AP (1970) Secular trends in mortality from malignant melanoma. J Natl Cancer Inst 45:91–97

    PubMed  CAS  Google Scholar 

  8. Magnus K (1973) Incidence of malignant melanoma of the skin in Norway, 1955–1970. Variations in time and space and solar radiation. Cancer 32:1275–1286

    Article  PubMed  CAS  Google Scholar 

  9. Osterlind A (1992) Epidemiology on malignant melanoma in Europe. Acta Oncol 31:903–908

    Article  PubMed  CAS  Google Scholar 

  10. Magnus K (1981) Habits of sun exposure and risk of malignant melanoma: an analysis of incidence rates in Norway 1955-1977 by cohort, sex, age, and primary tumor site. Cancer 48:2329–2335

    Article  PubMed  CAS  Google Scholar 

  11. Thorn M, Bergstrom R, Adami HO, Ringborg U (1990) Trends in the incidence of malignant melanoma in Sweden, by anatomic site, 1960–1984. Am J Epidemiol 132:1066–1077

    PubMed  CAS  Google Scholar 

  12. Scotto J, Pitcher H, Lee JA (1991) Indications of future decreasing trends in skin-melanoma mortality among whites in the United States. Int J Cancer 49:490–497

    Article  PubMed  CAS  Google Scholar 

  13. Newnham A, Moller H (2002) Trends in the incidence of cutaneous malignant melanomas in the south east of England, 1960–1998. J Public Health Med 24:268–275

    Article  PubMed  CAS  Google Scholar 

  14. Bulliard JL, Cox B (2000) Cutaneous malignant melanoma in New Zealand: trends by anatomical site, 1969–1993. Int J Epidemiol 29:416–423

    Article  PubMed  CAS  Google Scholar 

  15. Chen YT, Zheng T, Holford TR et al (1994) Malignant melanoma incidence in Connecticut (United States): time trends and age-period-cohort modeling by anatomic site. Cancer Causes Control 5:341–350

    Article  PubMed  CAS  Google Scholar 

  16. MacKie RM, Bray CA, Hole DJ et al (2002) Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 360:587–591

    Article  PubMed  Google Scholar 

  17. Stang A, Stang K, Stegmaier C et al (2001) Skin melanoma in Saarland: incidence, survival and mortality 1970-1996. Eur J Cancer Prev 10:407–415

    Article  PubMed  CAS  Google Scholar 

  18. Hemminki K, Zhang H, Czene K (2003) Incidence trends and familial risks in invasive and in situ cutaneous melanoma by sun-exposed body sites. Int J Cancer 104:764–771

    Article  PubMed  CAS  Google Scholar 

  19. Jemal A, Devesa SS, Hartge P, Tucker MA (2001) Recent trends in cutaneous melanoma incidence among whites in the united states. J Natl Cancer Inst 93:678–683

    Article  PubMed  CAS  Google Scholar 

  20. Surveillance, Epidemiology, and End Results (SEER) Program (2007) SEER*stat database: incidence — SEER 17 regs limited-use, Nov 2006 Sub (1973–2004 varying). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, USA. (released April 2007, based on the November 2006 submission). http://www.seer.cancer.gov

  21. La Vecchia C, Lucchini F, Negri E, Levi F (1999) Recent declines in worldwide mortality from cutaneous melanoma in youth and middle age. Int J Cancer 81:62–66

    PubMed  Google Scholar 

  22. Thorn M, Ponten F, Bergstrom R et al (1994) Trends in tumour characteristics and survival of malignant melanoma 1960–84: a population-based study in Sweden. Br J Cancer 70:743–748

    Article  PubMed  CAS  Google Scholar 

  23. Dennis LK (1999) Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol 135:275–280

    Article  PubMed  CAS  Google Scholar 

  24. Lipsker DM, Hedelin G, Heid E et al (1999) Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch Dermatol 135:1451–1456

    Article  PubMed  CAS  Google Scholar 

  25. Crocetti E, Carli PM (2003) Changes from mid-1980s to late 1990s among clinical and demographic correlates of melanoma thickness. Eur J Dermatol 13:72–75

    PubMed  Google Scholar 

  26. Mendonca GA (1992) [Increasing risk of skin melanoma in Brazil] Risco crescente de melanoma de pele no Brasil. Rev Saude Publica 26:290–294

    Article  PubMed  CAS  Google Scholar 

  27. Severi G, Giles GG, Robertson C et al (2000) Mortality from cutaneous melanoma: evidence for contrasting trends between populations. Br J Cancer 82:1887–1891

    Article  PubMed  CAS  Google Scholar 

  28. Abarca JF, Casiccia CC (2002) Skin cancer and ultraviolet-B radiation under the Antarctic ozone hole: southern Chile, 1987–2000. Photodermatol Photoimmunol Photomed 18:294–302

    Article  PubMed  Google Scholar 

  29. Koh D, Wang H, Lee J et al (2003) Basal cell carcinoma, squamous cell carcinoma and melanoma of the skin: analysis of the Singapore Cancer Registry data 1968–97. Br J Dermatol 148:1161–1166

    Article  PubMed  CAS  Google Scholar 

  30. Jin F, Devesa SS, Chow WH et al (1999) Cancer incidence trends in urban shanghai, 1972–1994: an update. Int J Cancer 83:435–440

    Article  PubMed  CAS  Google Scholar 

  31. English DR, Armstrong BK, Kricker A, Fleming C (1997) Sunlight and cancer. Cancer Causes Control 8:271–283

    Article  PubMed  CAS  Google Scholar 

  32. Khlat M, Vail A, Parkin M, Green A (1992) Mortality from melanoma in migrants to Australia: variation by age at arrival and duration of stay. Am J Epidemiol 135:1103–1113

    PubMed  CAS  Google Scholar 

  33. Cooke KR, Fraser J (1985) Migration and death from malignant melanoma. Int J Cancer 36:175–178

    Article  PubMed  CAS  Google Scholar 

  34. Steinitz R, Parkin DM, Young JL et al (1989) Cancer incidence in Jewish migrant to Israel, 1961–1981. IARC Scientific Publications No. 98. IARC Press, Lyon, p 306

    Google Scholar 

  35. Hinds MW, Kolonel LN (1980) Malignant melanoma of the skin in Hawaii, 1960–1977. Cancer 45:811–817

    Article  PubMed  CAS  Google Scholar 

  36. Ries L, Melbert D, Krapcho M et al (2007) SEER cancer statistics review, 1975–2004. National Cancer Institute, Bethesda

    Google Scholar 

  37. Parkin DM, Ferlay J, Hamdi-Cherif M et al (2003) Cancer in Africa: epidemiology and prevention. IARC Scientific Publications No. 153. IARCPress, Lyon

    Google Scholar 

  38. Ohtsuka H, Nagamatsu S (2003) Changing trends in numbers of deaths from malignant melanoma in Japan, 1955–2000. Dermatology 207:162–165

    Article  PubMed  Google Scholar 

  39. Cress RD, Holly EA (1997) Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of california cancer registry data, 1988–93. Cancer Causes Control 8:246–252

    Article  PubMed  CAS  Google Scholar 

  40. Registro Poblacional de Cáncer de Cali Colombia (2007) Melanoma y otros cáncers de piel. Tasa de mortalidad por melanoma y otros cáncer de piel especificas por edad, crudas y ajustadas por edad a la población estándar mundial durante el periodo 1984–2003. Cali Cancer Registry, California

    Google Scholar 

  41. Halder RM, Bridgeman-Shah S (1995) Skin cancer in African Americans. Cancer 75:667–673

    Article  PubMed  CAS  Google Scholar 

  42. Bellows CF, Belafsky P, Fortgang IS, Beech DJ (2001) Melanoma in African—Americans: trends in biological behavior and clinical characteristics over two decades. J Surg Oncol 78:10–16

    Article  PubMed  CAS  Google Scholar 

  43. Scarpa A, Guerci A (1987) Depigmenting procedures and drugs employed by melanoderm populations. J Ethnop-harmacol 19:17–66

    Article  CAS  Google Scholar 

  44. Harada M, Nakachi S, Tasaka K et al (2001) Wide use of skin-lightening soap may cause mercury poisoning in Kenya. Sci Total Environ 269:183–187

    Article  PubMed  CAS  Google Scholar 

  45. Armstrong BK, Kricker A (1993) How much melanoma is caused by sun exposure? Melanoma Res 3:395–401

    Article  PubMed  CAS  Google Scholar 

  46. Veierod MB, Weiderpass E, Thorn M et al (2003) A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst 95:1530–1538

    Article  PubMed  Google Scholar 

  47. Hemminki K, Zhang H, Czene K (2003) Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Invest Dermatol 120:217–223

    Article  PubMed  CAS  Google Scholar 

  48. Bishop JN, Harland M, Randerson-Moor J, Bishop DT (2007) Management of familial melanoma. Lancet Oncol 8:46–54

    Article  PubMed  CAS  Google Scholar 

  49. Bataille V (2003) Genetic epidemiology of melanoma. Eur J Cancer 39:1341–1347

    Article  PubMed  CAS  Google Scholar 

  50. Bishop DT, Demenais F, Goldstein AM et al (2002) Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94:894–903

    Article  PubMed  CAS  Google Scholar 

  51. Tucker MA, Goldstein AM (2003) Melanoma etiology: where are we? Oncogene 22:3042–3052

    Article  PubMed  CAS  Google Scholar 

  52. Green A, Trichopoulos D (2002) Skin cancer. In: Adami HO, Hunter D, Trichopoulos D (eds) Textbook of cancer epidemiology. Oxford University Press, New York, pp 281–300

    Google Scholar 

  53. Vainio H, Miller AB, Bianchini F (2000) An international evaluation of the cancer-preventive potential of sunscreens. Int J Cancer 88:838–842

    Article  PubMed  CAS  Google Scholar 

  54. Krone B, Kolmel KF, Grange JM et al (2003) Impact of vaccinations and infectious diseases on the risk of melanoma — evaluation of an EORTC case-control study. Eur J Cancer 39:2372–2378

    Article  PubMed  CAS  Google Scholar 

  55. Pfahlberg A, Botev IN, Kolmel KF, Gefeller O (2002) Vaccination and melanoma risk. Int J Cancer 102:96–97

    Article  PubMed  CAS  Google Scholar 

  56. Pfahlberg A, Kolmel KF, Grange JM et al (2002) Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. J Invest Dermatol 119:570–575

    Article  PubMed  CAS  Google Scholar 

  57. Kolmel KF, Grange JM, Krone B et al (2005) Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 41:118–125

    Article  PubMed  CAS  Google Scholar 

  58. Krone B, Kolmel KF, Henz BM, Grange JM (2005) Protection against melanoma by vaccination with Bacille Calmette—Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer 41:104–117

    Article  PubMed  CAS  Google Scholar 

  59. Mantzoros CS, Trakatelli M, Gogas H et al (2007) Circulating adiponectin levels in relation to melanoma: a case-control study. Eur J Cancer 43:1430–1436

    Article  PubMed  CAS  Google Scholar 

  60. Koomen E, Joosse A, Herings R et al (2007) Effect of statins on melanoma of the skin. Eur J Cancer 43:2580–2589

    Article  PubMed  CAS  Google Scholar 

  61. Fortes Deppermann C, De Vries E (2008) Non-solar occupational risk factors for cutaneous melanoma. Int J Dermatol 47:319–328

    Article  Google Scholar 

  62. MacKie RM (2000) Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol 25:471–475

    Article  PubMed  CAS  Google Scholar 

  63. Scottish Intercollegiate Guidelines Network (SIGN) (2003) Cutaneous melanoma. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN). (SIGN publication; no. 72), SIGN publication, Edinburgh, p 50

    Google Scholar 

  64. Duff CG, Melsom D, Rigby HS et al (2001) A 6 year prospective analysis of the diagnosis of malignant melanoma in a pigmented-lesion clinic: even the experts miss malignant melanoma, but not often. Br J Plast Surg 54:317–321

    Article  PubMed  CAS  Google Scholar 

  65. Richard MA, Grob JJ, Avril MF et al (2000) Delays in diagnosis and melanoma prognosis(II): the role of doctors. Int J Cancer 20(89):280–285

    Article  Google Scholar 

  66. Gerbert B, Maurer T, Berger T et al (1996) Primary care physicians as gatekeepers in managed care. Primary care physicians' and dermatologists' skills at secondary prevention of skin cancer. Arch Derm 132:1030–1038

    Article  PubMed  CAS  Google Scholar 

  67. McCarthy WH, Milton GW (2004) Primary cutaneous melanoma:clinical diagnosis. In: Thomson JF, Morton DL, Kroon BB (eds) Textbook of melanoma. Martin Dunitz, London

    Google Scholar 

  68. Friedman RJ, Rigel DS, Kopf AW (1985) Early detection of malignant melanoma: the role of physician examination and self examination of the skin. Cancer J Clin 35(3): 130–151

    Article  CAS  Google Scholar 

  69. Thomas L, Tranchand P, Berard F, Secchi T, Colin C, Moulin G (1998) Semiological value of ABCDE criteria in the diagnosis of cutaneous pigmented tumors. Dermatology 197(1):11–17

    Article  PubMed  CAS  Google Scholar 

  70. Whited JD, Grichnik JM (1998) The rational clinical examination. Does this patient have a mole or a melanoma? JAMA 279:696.

    Article  PubMed  CAS  Google Scholar 

  71. Friedman RJ (2005) The importance of early detection of melanoma, physician and self-examination. In: Rigell DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R (eds) Cancer of the skin. Elsevier, Amsterdam

    Google Scholar 

  72. Shaw HM, Mc Carthy WH (1992) Small diameter malignant melanoma: a common diagnosis in New South Wales, Australia. J Am Acad of Dermatol 27:679–682

    Article  CAS  Google Scholar 

  73. Fernandez EM, Helm KF (2004) The diameter of melanomas. Dermatol Surg 30:1219–1222

    Article  PubMed  Google Scholar 

  74. Roberts DLL, Anstey AV, Barlow RJ, Cox NH, on behalf of the British Association Of Dermatologists, Bishop JAN, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, on behalf of the Melanoma Study Group (2002) U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 146:7–17

    Google Scholar 

  75. MacKie RM (1989) Malignant Melanoma. A Guide to Early Diagnosis, Edinburgh

    Google Scholar 

  76. Gachon J, Beaulieu P, Sei JF, Gouvernet J, Claudel JP, Lemaitre M, Richard MA, Grob JJ (2005) First prospective study of the recognition process of melanoma in dermato-logical practice. Arch Dermatol 141:434–438

    Article  PubMed  Google Scholar 

  77. Menzies S, Stolz W (2004) Surface microscopy features of melanoma. In: Thomson JF, Morton DL, Kroon BB (eds) Textbook of melanoma. Martin Dunitz, London

    Google Scholar 

  78. Kittler H, Pehamberger H, Wolff K et al (2002) Diagnostic accuracy of dermoscopy. Lancet Oncol 3(3):159–165

    Article  PubMed  CAS  Google Scholar 

  79. Binder M, Schwarz M Winkler A et al (1995) Epiluminescence microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Derm 131:286–291

    Article  PubMed  CAS  Google Scholar 

  80. Soyer HP, Argemziano G, Chimenti S et al (2001) Dermoscopy of pigmented skin lesions: an atlas based on the consensus net meeting on dermoscopy 2000. Milan:EDRA Medical Publishing and New Media, Italy

    Google Scholar 

  81. Koller J, Rettenbacher L (2000) The influence of diagnostic biopsies on the sentinel lymph node detection in cutaneous melanoma. Arch Dermatol 136:1176

    Article  PubMed  CAS  Google Scholar 

  82. McKenna DB, Lee RJ, Prescott RJ, Doherty VR (2004) A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision. Br J Dermatol 150(3):523–530

    Article  PubMed  CAS  Google Scholar 

  83. Lees VC, Briggs JC (1991) Effect of initial biopsy procedure on prognosis in Stage I invasive cutaneous melanoma: a review of 1086 patients. Br J Surg 78:1108–1110

    Article  PubMed  CAS  Google Scholar 

  84. Bong JL, Herd RM, Hunter JA (2002) Incisional biopsy and melanoma pognosis. J Am Acad Dermatol 46:690–694

    Article  PubMed  Google Scholar 

  85. Boyd AD, Neldner KH (1997) How to submit a specimen for cutaneous pathology analysis: using the 5 Ds to get the most out of biopsies. Arch Fam Med 6:64–66

    Article  PubMed  CAS  Google Scholar 

  86. O'Connor KM, Chien AJ (2008) Management of melano-cytic lesions in the primary care setting. Mayo Clin Proc 83(2):208–214

    PubMed  Google Scholar 

  87. Markovic SN, Erickson LA, Rao RD et al (2007) Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 82:364–380

    PubMed  Google Scholar 

  88. Balch CM, Buzaid AC, Soong SJ et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635–3648

    PubMed  CAS  Google Scholar 

  89. Balch CM, Soong SJ, Gershenwald JE et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol Aug 15;19(16):3622–3634

    CAS  Google Scholar 

  90. Balch CM, Buzaid AC, Soong SJ et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648

    PubMed  CAS  Google Scholar 

  91. de Vries E, Nijsten T, Visser O et al (2007) Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 19:583–589

    Article  PubMed  Google Scholar 

  92. Sant M, Aareleid T, Berrino F et al (2003) EUROCARE-3: survival of cancer patients diagnosed 1990–94-results and commentary. Ann Oncol 14:Suppl 5: V61–V118

    Article  PubMed  Google Scholar 

  93. de Vries E, Boniol M, Doré JF et al (2004) Lower incidence rates but thicker melanomas in Eastern Europe preceding 1992: a comparison with Western Europe. Eur J Cancer 40:1045–1052

    Article  PubMed  Google Scholar 

  94. Burton RC, Armstrong BK (1994) Recent incidence trends imply a nonmetastasizing form of invasive melanoma. Melanoma Res 4:107–113

    Article  PubMed  CAS  Google Scholar 

  95. Welch HG, Woloshin S, Schwartz LM (2005) Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 331:481

    Article  PubMed  Google Scholar 

  96. Veronesi U, Cascinelli N, Adamus J et al (1988) Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm [published erratum appears in N Engl J Med 1991 Jul 25;325(4):292]. N Engl J Med 318:1159–1162

    Article  PubMed  CAS  Google Scholar 

  97. Cascinelli N (1995) Update WHO-10 trial. WHO-program meeting, May 1995. Albany; Personal Communication

    Google Scholar 

  98. Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA, Lauret P, Verola O, Auclerc G, Harper P, Banzet P; French Group of Research on Malignant Melanoma (2004) Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 97:1941–1946

    Article  Google Scholar 

  99. Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H, Jonsson PE, Krysander L, Lindholm C, Ringborg U (2000) Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 89:1495–1501

    Article  PubMed  CAS  Google Scholar 

  100. Balch CM, Urist MM, Karakousis CP et al (1993) Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial [see comments]. Ann Surg 218:262–267; discussion 267–269

    Article  PubMed  CAS  Google Scholar 

  101. Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, Temple WJ, Mihm MC, Barnhill RL, Jewell WR, Wanebo HJ, Desmond R (2001) Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol 8:101–108

    PubMed  CAS  Google Scholar 

  102. Heaton KM, Sussman JJ, Gershenwald JE et al (1998) Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol 5:322–328

    Article  PubMed  CAS  Google Scholar 

  103. Ringborg U, Mansson Brahme E, Drzewiecki K, Gullestadt HP, Ninn M (2005) Randomized trial of a resection margin of 2 cm versus 4 cm for cutaneous malignant melanoma with a tumor thickness of more than 2 mm. Proceedings 6th world melanoma congress, Vancouver, September 6–10; Abstract 28

    Google Scholar 

  104. Thomas JM, Newton-Bishop J, A'Hern R, Coombes G, Timmons M, Evans J, Cook M, Theaker J, Fallowfield M, O'Neill T, Ruka W, Bliss JM; United Kingdom Melanoma Study Group (2004) British Association of Plastic Surgeons; Scottish Cancer Therapy Network. Excision margins in high-risk malignant melanoma. N Engl J Med 350(8): 757–766

    Article  PubMed  CAS  Google Scholar 

  105. Veronesi U, Adamus J, Bandiera DC et al (1977) Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 297:627–630

    Article  PubMed  CAS  Google Scholar 

  106. Sim FH, Taylor WF, Ivins JC et al (1978) A prospective randomized study of the efficacy of routine elective lymph-adenectomy in management of malignant melanoma. Preliminary results. Cancer 41:948–956

    Article  PubMed  CAS  Google Scholar 

  107. Balch CM, Soong S, Ross MI et al (2000) Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 7:87–97

    Article  PubMed  CAS  Google Scholar 

  108. Cascinelli N, Morabito A, Santinami M et al (1998) Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 351:793–796

    Article  PubMed  CAS  Google Scholar 

  109. Gershenwald JE, Thompson W, Mansfield PF et al (1999) Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17:976–983

    PubMed  CAS  Google Scholar 

  110. Vuylsteke RJ, van Leeuwen PA, Statius Muller MG et al (2003) Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 21:1057–1065

    Article  PubMed  CAS  Google Scholar 

  111. Doubrovsky A, De Wilt JH, Scolyer RA et al (2004) Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. Ann Surg Oncol 11:829–836

    Article  PubMed  CAS  Google Scholar 

  112. van Akkooi AC, de Wilt JH, Verhoef C, Graveland WJ, van Geel AN, Kliffen M, Eggermont AM (2006) High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 42:372–380

    Article  PubMed  Google Scholar 

  113. van Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, Kliffen M (2006) Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 17(10):1578–1585

    Article  PubMed  Google Scholar 

  114. van Akkooi AC, Nowecki ZI, Voit C, Schaefer G, Michej W, Kliffen M, Schmitz PIM, Ruka W, Eggermont AMM (2007) Prognosis depends on micro-anatomic patterns of melanoma micrometastases within the sentinel node (SN). A multicenter study in 388 SN positive patients. Eur J Cancer Suppl 5(4):397; abstract 7006

    Article  Google Scholar 

  115. van Akkooi AC, Bouwhuis MG, de Wilt JH, Kliffen M, Schmitz PI, Eggermont AM (2007) Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma. Br J Surg 94(10):1293–1299

    Article  PubMed  Google Scholar 

  116. Eggermont AM, Gore M (2007) Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol 34(6):509–515

    Article  PubMed  Google Scholar 

  117. Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H, Simes RJ (2002) Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 20(20):4181–4190

    Article  PubMed  CAS  Google Scholar 

  118. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE (2002) Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20(8):2058–2066

    Article  PubMed  CAS  Google Scholar 

  119. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK; Southwest Oncology Group (2002) Adjuvant immunother-apy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 20(8):2067–2075

    Article  PubMed  CAS  Google Scholar 

  120. Morton DL (2006) Plenary presentation at Annual Meeting of the Society of Surgical Oncology. Plenary Presentation, Atlanta

    Google Scholar 

  121. Eggermont AMM (2001) Role of interferon in melanoma remains to be determined. Eur J Cancer 2147–2153

    Google Scholar 

  122. Gogas H, Dafni U, Bafaloukos D, Polyzos A, Kokkalis G, Kalofonos HP, Fountzilas G, Skarlos D, Tsoutsos D, Pectasides D (2007) A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma. Proc ASCO 43rd Annual Meeting: 25; Abstract 8505

    Google Scholar 

  123. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D; EORTC Melanoma Group (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366:1189–1196

    Article  PubMed  CAS  Google Scholar 

  124. Eggermont AMM, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Hauschild A, Gore M, Keilholz U; For the EORTC Melanoma Group (2007) EORTC 18991: long term adjuvant pegylated interferon-α2b (PEG-IFN) vs observation in resected stage III melanoma: final results of a randomized phase 3 trial. Proc ASCO 43rd Annual Meeting: 25; Abstract 8504

    Google Scholar 

  125. Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20:1818–1825

    Article  PubMed  CAS  Google Scholar 

  126. Wheatley K, Ives N, Hancock B, Gore M, Eggermont AMM, Suciu S (2003) Does adjuvant interferon-alpha provide a worth-while benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241–252

    Article  PubMed  CAS  Google Scholar 

  127. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U (2004) A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10:1670–1677

    Article  PubMed  CAS  Google Scholar 

  128. Wheatley K, Ives N, Eggermont AM, Kirkwood J, Cascinelli N, Markovic S, Hancock B, Lee S, Suciu S, on behalf of the International Malignant Melanoma Collaborative Group (2007) Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of the randomised trials. Proc ASCO 43rd Annual Meeting: 25; Abstract 8526

    Google Scholar 

  129. Grob JJ, Dreno B, Chastang C, Guillot B, Cupissol B, Souteyrand P et al (1998) Randomised trial of interferon a-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. Lancet 351:1905–1910

    Article  PubMed  CAS  Google Scholar 

  130. Pehamberger H, Soyer HP, Steiner A et al (1998) Adjuvant Interferon alpha 2-A treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 16:1425–1429

    PubMed  CAS  Google Scholar 

  131. Cameron DA, Cornbleet MC, MacKie RM, Hunter JAA, Gore M, Hancock B, Smyth JF (2001) Adjuvant interferon alpha in high risk melanoma: The Scottish study. Br J Cancer 84:1146–1149

    Article  PubMed  CAS  Google Scholar 

  132. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354(7):709–718

    Article  PubMed  CAS  Google Scholar 

  133. Bouwhuis M, Suciu S, Kruit W, Salès F, Patel P, Punt C, Stoitchkov K, Delaunay M, ten Hagen T, Eggermont AM; EORTC Melanoma Group (2007) Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) vs observation (Obs). Proc ASCO 43rd Annual Meeting: 25; Abstract 8507

    Google Scholar 

  134. Stuckert IIJJ, Tarhini AA, Lee S, Sander C, Kirkwood JM (2007) Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696. Proc ASCO 43rd Annual Meeting: 25; Abstract 8506

    Google Scholar 

  135. Bouwhuis M, Suciu S, Testori A, Santinami M, Kruit W, Punt C, Salès F, Patel P, Spatz A, Eggermont AMM (2007) Prognostic value of autoantibodies (auto-AB) in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon a2b (PEG-IFN) vs Observation. Eur J Cancer Suppl 5(6):11; abstract 3BA

    Article  Google Scholar 

  136. Suciu S, Ghanem G, Kruit W, Stoitchkov K, Patel P, Delaunay M, Salès F, Eggermont AM, on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group (2007) Serum S-100B protein is a strong independent prognostic marker for distant-metastasis free survival (DMFS) in stage III melanoma patients: an evaluation of the EORTC 18952 trial comparing Interferon (IFN) vs Observation. Proc ASCO 43rd Annual Meeting: 25; Abstract 8518

    Google Scholar 

  137. Atkins MB (2006) Cytokine-based therapy and biochemo-therapy for advanced melanoma. Clin Cancer Res 12(7 Pt 2):2353s–2358s

    Article  PubMed  CAS  Google Scholar 

  138. Schwimmer J et al (2000) A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 44(2):153–617

    PubMed  CAS  Google Scholar 

  139. Skibber JM et al (1996) Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 3(2):118–213

    Article  PubMed  CAS  Google Scholar 

  140. Fife KM et al (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22(7):1293–3100

    Article  PubMed  CAS  Google Scholar 

  141. McWilliams RR et al (2003) Treatment of brain metastases from melanoma. Mayo Clin Proc 78(12):1529–3156

    Article  PubMed  Google Scholar 

  142. Wronski M, Arbit E (2000) Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 93(1):9–18

    Article  PubMed  CAS  Google Scholar 

  143. Zacest AC et al (2002) Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg 96(3):552–855

    Article  PubMed  Google Scholar 

  144. Gieger M et al (1997) Response of intracranial melanoma metastases to stereotactic radiosurgery. Radiat Oncol Investig 5(2):72–80

    Article  PubMed  CAS  Google Scholar 

  145. Samlowski WE et al (2007) Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 109(9):1855–6182

    Article  PubMed  Google Scholar 

  146. Somaza S et al (1993) Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg 79(5):661–666

    Article  PubMed  CAS  Google Scholar 

  147. Hagen NA et al (1990) The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 40(1):158–610

    Article  PubMed  CAS  Google Scholar 

  148. Vermeulen SS (1998) Whole brain radiotherapy in the treatment of metastatic brain tumors. Semin Surg Oncol 14(1):64–96

    Article  PubMed  CAS  Google Scholar 

  149. Patel JK et al (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135(6):807–180

    Article  PubMed  CAS  Google Scholar 

  150. Overett TK, Shiu MH (1985) Surgical treatment of distant metastatic melanoma. Indications and results. Cancer 56(5):1222–3120

    Article  PubMed  CAS  Google Scholar 

  151. Overgaard J et al (1986) Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 5(3):183–912

    Article  PubMed  CAS  Google Scholar 

  152. Sause WT et al (1991) Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 20(3):429–342

    Article  PubMed  CAS  Google Scholar 

  153. Day CL Jr et al (1982) A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg 195(1):44–94

    Article  PubMed  Google Scholar 

  154. Agarwala SS, Kirkwood JM (1996) Interferons in melanoma. Curr Opin Oncol 8(2):167–714

    Article  PubMed  CAS  Google Scholar 

  155. Dummer R et al (2006) Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 24(7):1188–9114

    Article  PubMed  CAS  Google Scholar 

  156. Rosenberg SA et al (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161(5):1169–8118

    Article  PubMed  CAS  Google Scholar 

  157. Dutcher JP et al (1989) A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with meta-static malignant melanoma. J Clin Oncol 7(4):477–845

    PubMed  CAS  Google Scholar 

  158. Parkinson DR et al (1990) Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 8(10):1650–6165

    PubMed  CAS  Google Scholar 

  159. Atkins MB et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105–1216

    PubMed  CAS  Google Scholar 

  160. McCarter MD et al (2007) Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol 14(10):2854–6280

    Article  PubMed  Google Scholar 

  161. Rosenberg SA et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lym-phokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316(15):889–987

    Article  PubMed  CAS  Google Scholar 

  162. Yang JC, Rosenberg SA (1988) Current approaches to the adoptive immunotherapy of cancer. Adv Exp Med Biol 233:459–647

    PubMed  CAS  Google Scholar 

  163. Dudley ME et al (2002) Cancer regression and autoimmu-nity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850–485

    Article  PubMed  CAS  Google Scholar 

  164. Dudley ME et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346–5237

    Article  PubMed  CAS  Google Scholar 

  165. Sparano JA et al (1993) Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11(10):1969–7197

    PubMed  CAS  Google Scholar 

  166. Keilholz U et al (1995) Interleukin-2-based immunother-apy and chemoimmunotherapy in metastatic melanoma. Recent Results Cancer Res 139:383–930

    Article  PubMed  CAS  Google Scholar 

  167. Eton O et al (2000) A phase II study of “decrescendo” interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy. Cancer 88(7):1703–9170

    Article  PubMed  CAS  Google Scholar 

  168. Atkins MB (1998) Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin North Am 12(4):877–902, viii

    Article  PubMed  CAS  Google Scholar 

  169. Schiller JH et al (1996) Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res 2(1):29–36

    PubMed  CAS  Google Scholar 

  170. Atkins MB et al (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3(3):409–147

    PubMed  CAS  Google Scholar 

  171. Robertson MJ et al (2006) Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 12(14 Pt 1):4265–7423

    Article  PubMed  CAS  Google Scholar 

  172. Atallah E, Flaherty L (2005) Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6(3):185–913

    Article  PubMed  Google Scholar 

  173. Hill GJ III, Krementz ET, Hill HZ (1984) Dimethyl triaz-eno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53(6):1299–3105

    Article  PubMed  Google Scholar 

  174. Serrone L et al (2000) Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 19(1):21–34

    PubMed  CAS  Google Scholar 

  175. Middleton MR et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1):158–616

    PubMed  CAS  Google Scholar 

  176. Hwu WJ et al (2003) Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21(17):3351–6335

    Article  PubMed  CAS  Google Scholar 

  177. Hwu WJ et al (2002) Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol 20(11):2610–5261

    Article  PubMed  CAS  Google Scholar 

  178. Atkins MB (1997) The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. In: Kirkwood JK (ed) Molecular diagnosis, prevention & therapy of melanoma. Marcel Dekker, New York, p 219

    Google Scholar 

  179. Buzaid AC, Murren J (1992) Chemotherapy for advanced malignant melanoma. Int J Clin Lab Res 21(3):205–920

    Article  PubMed  CAS  Google Scholar 

  180. Del Prete SA et al (1984) Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in meta-static melanoma. Cancer Treat Rep 68(11):1403–5140

    PubMed  Google Scholar 

  181. Legha SS et al (1989) A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacar-bazine (CVD) for metastatic melanoma. Cancer 64(10):2024–9202

    Article  PubMed  CAS  Google Scholar 

  182. Saba HI et al (1992) Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg 28(1):65–96

    Article  PubMed  CAS  Google Scholar 

  183. Chapman PB et al (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9):2745–5271

    PubMed  CAS  Google Scholar 

  184. Chaudhuri PK et al (1980) Incidence of estrogen receptor in benign naevi and human malignant melanoma. JAMA 244(8):791–379

    Article  PubMed  CAS  Google Scholar 

  185. Conybeare RC (1964) Malignant melanoma and pregnancy: report of 3 Cases. Obstet Gynecol 24:451–445

    PubMed  CAS  Google Scholar 

  186. Reimer RR, Costanzi J, Fabian C (1982) Southwest Oncology Group experience with tamoxifen in metastatic melanoma. Cancer Treat Rep 66(8):1680–1168

    PubMed  CAS  Google Scholar 

  187. Cocconi G et al (1992) Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327(8):516–253

    Article  PubMed  CAS  Google Scholar 

  188. Creagan ET et al (1999) Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 17(6):1884–9180

    PubMed  CAS  Google Scholar 

  189. Kaufmann R et al (2005) Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 23(35):9001–7900

    Article  PubMed  CAS  Google Scholar 

  190. Falkson CI et al (1998) Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16(5):1743–5171

    PubMed  CAS  Google Scholar 

  191. Dummer R et al (1995) A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomoni-toring. Cancer 75(4):1038–4104

    CAS  Google Scholar 

  192. Stoter G et al (1991) Sequential administration of recombi-nant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol 9(9):1687–9161

    PubMed  CAS  Google Scholar 

  193. Keilholz U et al (1997) Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15(7):2579–8258

    PubMed  CAS  Google Scholar 

  194. Rosenberg SA et al (1999) Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17(3):968–795

    PubMed  CAS  Google Scholar 

  195. Ridolfi R et al (2002) Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20(6):1600–7160

    Article  PubMed  CAS  Google Scholar 

  196. Keilholz U et al (2005) Dacarbazine, cisplatin, and inter-feron-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23(27):6747–5675

    Article  PubMed  CAS  Google Scholar 

  197. Bajetta E et al (2006) Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 17(4):571–757

    Article  PubMed  CAS  Google Scholar 

  198. Eton O et al (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20(8):2045–5202

    Article  PubMed  CAS  Google Scholar 

  199. Atkins MB et al (2003) A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 22:708

    Google Scholar 

  200. Thurin J et al (1986) GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Lett 208(1):17–22

    Article  PubMed  CAS  Google Scholar 

  201. Kirkwood JM, Moschos S, Wang W (2006) Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res 12(7 Pt 2):2331s–2336s

    Article  PubMed  CAS  Google Scholar 

  202. Chan AD, Morton DL (1998) Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol 25(6):611–262

    PubMed  CAS  Google Scholar 

  203. Faries MB, Morton DL (2005) Therapeutic vaccines for melanoma: current status. BioDrugs 19(4):247–620

    Article  PubMed  CAS  Google Scholar 

  204. Trakatelli M et al (2006) A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother 55(4):469–744

    Article  PubMed  CAS  Google Scholar 

  205. Dillman RO, Selvan SR, Schiltz PM (2006) Patient-specific dendritic-cell vaccines for metastatic melanoma. N Engl J Med 355(11):1179–8111

    Article  PubMed  CAS  Google Scholar 

  206. Trakatelli M et al (2005) Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes. Cancer Gene Ther 12(6):552–955

    Article  PubMed  CAS  Google Scholar 

  207. Nawrocki S et al (2000) Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett 74(1):81–68

    Article  PubMed  CAS  Google Scholar 

  208. Soiffer R et al (2003) Vaccination with irradiated, autolo-gous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21(17):3343–5330

    Article  PubMed  CAS  Google Scholar 

  209. Eisen T et al (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95(5):581–658

    Article  PubMed  CAS  Google Scholar 

  210. Flaherty KT (2006) Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 12(7 Pt 2):2366s–2370s

    Article  PubMed  CAS  Google Scholar 

  211. Agarwala SS et al (2007) Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. Proc Asco Annual Meeting Part I, J Clin Oncol 25(18S):8510

    Google Scholar 

Further Reading

  • Eggermont AMM, Gore M (2002) European approach to adjuvant treatments of intermediate- and high-risk malignant melanoma. Semin Oncol 29(4):382–388 (Review)

    Article  PubMed  Google Scholar 

  • Morton DL, Wen DR, Wong JH et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392–399

    Article  PubMed  CAS  Google Scholar 

  • Koskivuo I, Talve L, Vihinen P, Mäki M, Vahlberg T, Suominen E (2007) Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Ann Surg Oncol 14(12):3566–3574

    Article  PubMed  Google Scholar 

  • Morton DL, Thompson JF, Cochran AJ, Essner R, Elashoff R; Multicenter Selective Lymphadenectomy Trial Group (2005) Interim results of the Multicenter Selective Lymphadenec-tomy Trial (MSLT-I) in clinical stage I melanoma. J Clin Oncol Supplement ASCO meeting abstracts 23:7500;http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19-003013,00.asp

  • Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ;MSLT Group (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355(13):1307–1317

    Article  PubMed  CAS  Google Scholar 

  • Thomas JM, Clark MA (2004) Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/ in-transit recurrence in malignant melanoma. Eur J Surg Oncol 30(6):686–691

    Article  PubMed  CAS  Google Scholar 

  • Kretschmer L, Beckmann I, Thoms KM, Haenssle H, Bertsch HP, Neumann C (2005) Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas. Eur J Cancer 41:531–538

    Article  PubMed  CAS  Google Scholar 

  • van Poll D, Thompson JF, Colman MH et al (2005) A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 12(8):597–608

    Article  PubMed  Google Scholar 

  • Kang JC, Wanek LA, Essner R, Faries MB, Foshag LJ, Morton DL (2005) Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol 23(21):4764–4770

    Article  PubMed  Google Scholar 

  • Pawlik TM, Ross MI, Thompson JF, Eggermont AMM, Gerschenwald JE (2005) The risk of in-transit metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 23:4588–9450

    Article  PubMed  Google Scholar 

  • Eggermont AMM (2000) Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Recent Results Cancer Res 157:178–189

    Article  PubMed  CAS  Google Scholar 

  • Voit C, Mayer T, Kron M et al (2001) Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients. Cancer 91:2409–2416

    Article  PubMed  CAS  Google Scholar 

  • Voit C, Schoengen A, Schwurzer-Voit M et al (2002) The role of ultrasound in detection and management of regional disease in melanoma patients. Semin Oncol 29:353–360

    Article  PubMed  Google Scholar 

  • Eggermont AMM (2005) Reducing the need for sentinel node procedures by ultrasound examination of regional lymph nodes. Ann Surg Oncol 12(1):3–5

    Article  PubMed  Google Scholar 

  • Voit C, Kron M, Schafer G, Schoengen A, Audring H, Lukowsky A, Schwurzer-Voit M, Sterry W, Winter H, Rademaker J (2006) Ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol 12:1682–1689

    Article  Google Scholar 

  • Voit CA, van Akkooi ACJ, Schaefer-Hesterberg G, Schoengen A, Sterry W, Eggermont AMM (2007) Reduction of need for operative sentinel node procedure in melanoma patients: fifty percent identification rate of sentinel node positivity by ultrasound (US)-guided fine needle aspiration cytology (FNAC) in 400 consecutive patients. Eur J Cancer — Supplements 5(6):11; abstract 3BA

    Article  Google Scholar 

  • Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, Eggermont AM, Di Filippo F, Krementz ET, Ruiter D, Lejeune FJ (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 9:2906–2912

    Google Scholar 

  • Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JHW, Eggermont AMM (2004) One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 240:939–947

    Article  PubMed  Google Scholar 

  • Grünhagen DJ, van Etten B, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM (2005) Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 12(8):597–608

    Article  Google Scholar 

  • Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL (2002) Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20(23):4549–4554

    Article  PubMed  CAS  Google Scholar 

  • Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G et al (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 5:1036–1044

    Google Scholar 

  • Laber DA et al (2006) A phase II study of extended dose temozolo-mide and thalidomide in previously treated patients with meta-static melanoma. J Cancer Res Clin Oncol 132(9):611–661

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Venerology, Papageorgiou Hospital, Ring Road N.Efkarpia, 56403, Thessaloniki, Greece

    Myrto Trakatelli

Authors
  1. Myrto Trakatelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Esther de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Katsanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dimitris Tzachanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexander Eggermont
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Myrto Trakatelli .

Editor information

Editors and Affiliations

  1. Skin Cancer Center Charité, Department of Dermatology, Charité University Medicine Berlin, Charitéplatz 1, Berlin, 10117, Germany

    Eggert Stockfleth

  2. Department of Dermatology, 6620 Main Street, Suite 1425, Houston, TX, 77030, USA

    Theodore Rosen (Chief of VA Dermatology Clinic Professor) (Chief of VA Dermatology Clinic Professor)

  3. Ground Floor, 225 Macquarie Street, Sydney, NSW, 2000, Australia

    Stephen Shumack

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Trakatelli, M., Vries, E.d., Katsanos, G., Tzachanis, D., Eggermont, A. (2010). Cutaneous Malignant Melanoma. In: Stockfleth, E., Rosen, T., Shumack, S. (eds) Managing Skin Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79347-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-79347-2_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-79346-5

  • Online ISBN: 978-3-540-79347-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation